Received Mar 7, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HIBV | HIB (PEDVAXHIB) | MERCK & CO. INC. | 1 | Y006393 | — |
| PNC15 | PNEUMO (VAXNEUVANCE) | MERCK & CO. INC. | 1 | Y005465 | — |
| RV5 | ROTAVIRUS (ROTATEQ) | MERCK & CO. INC. | 1 | Y009341 | OT |
No additional AE reported; VFC immunization coordinator calling to report T/E for PEDVAX HIB , ROTATEQ, VAXNEUVANCE that was administered. T/E date was on 2/18/2025 and PEDVAX HIB , ROTATEQ, VAXNEUVANCE were administered on 3/03/2025. Permission was given to contact HCP; This spontaneous report has been received from a nurse and refers to a patient of unknown age and gender. There was no information regarding the patient's medical history, concurrent conditions and concomitant medications provided. On 03-MAR-2025, the patient was vaccinated with the first doses of haemophilus b conjugate (PEDVAXHIB-LIQUID) suspension for injection, lot # Y006393, expiration date 07-NOV-2026 (exact dose, route of administration and anatomical location were not reported); and 15-valent pneumococcal conjugate vaccine (VAXNEUVANCE) suspension for injection, lot # Y005465, expiration date 08-JAN-2027 (exact dose, route of administration and anatomical location were not reported); and rotavirus vaccine, live, oral, pentavalent (ROTATEQ) oral solution, lot # Y009341, expiration date: 24-NOV-2025, administered orally (exact dose was not reported), all for prophylaxis. The aforementioned doses of vaccines underwent a temperature excursion of 32.0 Fahrenheit (F) degrees for 2 hours and 12 minutes on 18-FEB-2025 (Product storage error). There was no previous temperature excursion. No additional adverse event was reported.